ArticleCureus2026
A Multimodal Quality Improvement Approach to Reduce Sevoflurane Consumption and Greenhouse Gas Emissions in an Academic Health System.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction Volatile anesthetics are major contributors to healthcare-related greenhouse gas (GHG) emissions. After eliminating desflurane from our formulary, we implemented a multimodal quality improvement (QI) initiative to reduce sevoflurane use by adopting low fresh gas flow (FGF) practices. Methods This QI project was conducted at two campuses of the University of Minnesota Medical Center (41 operating rooms, ~1,400 cases/month). Interventions between May 2024 and February 2025 included provider education, standardized workflows, monthly data feedback, and anelectronic health record (EHR) best practice alert (BPA) prompting lower FGF use. FGF metrics were derived from intraoperative data with specific inclusion and exclusion criteria, while sevoflurane volume and cost data were obtained directly from SlicerDicer and pharmacy purchase records. Outcomes were analyzed using control charts and two-sample t-tests comparing pre-intervention (January 2023-April 2024) and post-intervention (May 2024-June 2025) periods. Results A total of 42,416 general anesthetic cases using sevoflurane met the inclusion criteria. The proportion of cases with average FGF < 2 L/min during the maintenance phase increased from 18.2% to 55.0% (3,886/21,122; 10,323/18,775) (p < 0.001), while those never below 2 L/min decreased from 52.7% to 14.8% (11,128/21,122; 2,812/18,775) (p < 0.001). Mean monthly sevoflurane use declined from 9,785 L to 7,475 L, corresponding to an annual reduction of 35,277 L (approximately 45,000 kg CO₂e) and a net cost savings of approximately $38,000. Conclusions At a single academic institution, a multimodal, data-driven QI initiative integrating staff education, workflow optimization, the EHR, and low-flow anesthesia significantly reduced sevoflurane consumption, resulting in net cost savings and a positive environmental impact.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.